It has been about six years since publication of the first papers to demonstrate the feasibility of mutating a specific mouse gene by homologous recombination in embryonic stem cells and of then transferring the mutation into a developing mouse. This ability to engineer specific mutations represented a major breakthrough in mouse genetics, and many excellent reviews discussing its development and implementation have been published (for example [1] [2] [3] ). The most common point of this exercise has been to inactivate the targeted gene and to observe the phenotypic effects of the 'knockout' on the developing mouse. A number of reviews describing results from knockout mice relevant to specific areas of mammalian biology have been published (for example [4] [5] [6] ). The purpose of this article is to provide a compendium of the gene-targeted mutations that have been published, with the hope that this will become the foundation for an active database that will keep track of this burgeoning field.
Logistics
In developing two tables of knockouts, we have attempted to compile all of the published genomic modifications that have been established in murine embryonic stem cells by homologous recombination, passed through the germ line of chimeric mice, and then studied in resulting heterozygous, hemizygous and/or homozygous animals. In most cases, the result of targeting has been a null mutation, but truncations and subtle modifications of the protein coding sequence, as well as modifications of non-coding sequences, are also included in our compendium. This is clearly a limited subset of a large group of interesting mouse mutants, including those that have occurred spontaneously or have been developed by random integration of transgenes or viral sequences. However, Table 1 does include the majority of mouse mutants for which the exact gene mutation has been characterized. In several cases a targeted mutation has produced a phenotype similar to a previously studied mouse mutant, and has thus facilitated the molecular characterization of the previously established mutant [7-131. The first column of Table 1 gives the name of the protein product of the targeted gene (with abbreviated and/or alternative names in parentheses), or a description of the targeted genomic locus if it is not a coding sequence. If the entry is not a null mutant, this is also indicated by, for example, 'modification' or 'partial' (a 'leaky' mutation). The table is alphabetized by the first column. In cases where more than one group has performed essentially the same mutation, the number of independent groups is indicated in the second column (e.g. x2, x3). Also in the second column, we note if the mutant has been crossed with another mutant derived by gene targeting, and studied as a double mutant; this is indicated by a 'D', preceded by the number of different double mutants (e.g. D, 2D). The double mutants are described in a separate table (Table 2) which will be published in part III in a subsequent issue. The third column gives a synopsis of the key aspects of the phenotype, generally those reported in the primary reference(s) listed in the fourth column. By necessity, this description is superficial, and we direct the reader to the primary sources for more critical and in-depth analyses. When embryonic lethality is associated with the mutation, this is indicated by an 'e' followed by the day(s) of gestation when the mutants die. Perinatal lethality is defined as death within the first 24-48 hours after birth, and neonatal lethality is death before weaning. In many cases the perinatal and neonatal lethality is highly variable and may depend on the genetic background or environment, and again the reader is referred to the primary references for the precise details.
In a few instances, when more than one group has created essentially the same mutant, disparate results have been reported. Regardless of the reason for the disagreement, these findings are marked with a * in the third column. The fourth column gives the reference(s) that first described the mutant, while the fifth column lists subsequent reports describing the mutant, or utilizing the mutant as a tool for other experiments.
We have attempted to be comprehensive through 1994 in our compilation, and have also included some reports published in the first quarter of 1995. It is likely, however, that our search strategies (scanning major journals and searching Medline and Reference Update by key words) have inadvertently missed important references through 1994. We apologize to any researchers whose mutants or follow-up studies have escaped our attention and urge authors to submit this information to Current Biology for inclusion in updates to the database. A box on the next page tells you how to do this.
Observations
A total of 327 independently derived mutants are included in this table. However, essentially only 263 fundamentally different protein disruptions (or genetic modifications) have been performed, as 52 null mutations have been established independently by two different groups, and six by three groups. This degree of duplication of knockouts is not particularly surprising given the number of groups that have focused their research efforts on the same genes, and merely attests to the allure of the approach. It seems that certain types of protein have been preferentially studied so far (for example, those involved in immune responses or embryonic development). But the range is now expanding as the technology becomes more accessible.
In certain cases, unexpected roles for a protein have been discovered. In other cases, genetic redundancy or compensation has allowed partial function despite the absence of a protein thought to be crucial. In fact, out of the 263 knockouts listed in the table, only about 25 % lead to lethality before or just after birth, with another 10 % resulting in death during the first three to six weeks. Most null mutants, however, survive into adulthood. A common early misconception -that null mutants often have no observable defects -can be dispelled by the compendium. In fact, only a dozen or so of the mutants are apparently normal, and we suspect that, given further study, defects will be discovered in some of these mutants as well.
Several null mutants have demonstrated a surprisingly high degree of phenotypic variability between individual mice. This is probably due to the mixed genetic background on which the mutants are often initially derived, a contention supported by the reduction in variability observed when mutations are placed onto uniform inbred backgrounds [14] [15] [16] [17] . Additionally, environmental factors (such as the position of the embryo in utero or the animals' housing conditions) may be at least partially res' ponsible for phenotypic variations between individuals, and especially for those found between similar mutants performed by independent groups.
Future
What can we predict for the future of this technology?
While it certainly appears that many more gene knockouts will be reported, extrapolation of the number published per year ( Fig. 1 ) suggests that the rate may level off at a few hundred new reports per year. A number of factors could serve to limit this rate, including the relatively large financial cost of both mouse colonies and technical support. However, the payoff is great: the gene disruptions already available have facilitated research in virtually all areas of mammalian physiology and cell biology, and there will be further benefits from studies using either mutant mice or cells derived from these animals. This collection of mutant animals provides a compelling resource for the future of biomedical research and a vital counterpart to the human and mouse genome sequencing projects. Knockout mice have not always provided straightforward answers to pressing questions, and this has led to a certain amount of disillusionment with the approach itself. Indeed, many mutants created by gene targeting have resulted more in confusion than clarification. But with the emergence of more questions than answers it becomes clearer than ever just how complex many mammalian systems are, and entire new areas of investigation are sometimes opened up. The future holds the promise of producing mice carrying specific mutations in genes rather than complete null mutants. Tissuespecific or developmentally regulated mutations are now also feasible, and these techniques should allow a much more focused analysis of specific gene function. A largely unexplored area of research involves the development of either primary or established cell lines from null mutant mice; these cells should prove valuable in studies of the functional roles of gene products without the complicated context of the whole animal. Thus, the knockout mice represent not an end point but a starting point. Behavioral and anatomical deficits in mice homozygous for a modified beta-amyloid precursor protein gene. 
